<DOC>
	<DOCNO>NCT00867360</DOCNO>
	<brief_summary>The purpose research study see certain hormone cause change mood think depressed patient determine effectiveness mifepristone treat form depression . This study conduct conjunction observational study `` Clinical Biological Characteristics Psychotic Depression '' .</brief_summary>
	<brief_title>Treatment Psychotic Major Depression With Mifepristone</brief_title>
	<detailed_description>Eligibility Procedures : Before enter study prior procedure , ask read sign consent form . To determine eligible study , general medical ( include menstrual cycle history female patient ) psychiatric history take , physical examination , vital sign ( blood pressure , pulse ) , height , weight waist/hip ratio measure , well various psychiatric evaluation conduct . You randomly ( chance ) assign receive mifepristone placebo ( inactive substance ) . Half participant research study receive placebo , half receive mifepristone . Neither study doctor know two receive . Treatment begin morning Treatment Day 1 conclude Treatment Day 8 total treatment period 8 day . You take medication day morning . The dose originally 600 mg change 1200 mg per day 4th patient . You able take new medication ( study drug ) make change current medication participate part study unless order study physician . On treatment Day 1 , come office interview evaluate mood psychiatric symptom . Additionally , take vital sign draw blood administer clinical laboratory test . You meet study physician give 4-days medication take home self-administer morning . On Treatment Day 4 , come back office . We evaluate mood , take vital sign meet study physician . It important discus study physician research study staff unpleasant unusual symptom may experience . Any positive effect experience discuss well . You give additional 4-days medication take home self-administer morning . On Treatment Day 8 , re-evaluate mood , take vital sign repeat blood urine lab test . You also meet study physician discus side effect . If participate blood draw portion study , admit GCRC day overnight stay . At 2pm Treatment Day 8 , IV line insert one arm hourly blood sample 2pm , 4pm , 6pm 9am Treatment Day 9 . At 9am treatment Day 9 , 10 ml blood take Mifepristone concentration . A total 82mls ( approximately 5.5 tablespoon ) blood drawn . You discharge GCRC follow breakfast . On Treatment Day 15 , re-evaluate mood meet study physician discuss side effect . On Treatment Day 22 , readmitted GCRC , nurse take vitals sign repeat clinical laboratory test . We also reevaluate mood , meet study physician discuss side effect . If participated portion baseline protocol ( protocol # 13088 ) repeat neuropsychological , MRI blood draw procedure accordingly . If participate baseline protocol , assess safety discharge . You another functional MRI ( picture take brain use magnet administer series task ) . This MRI scan procedure take approximately 1 hour . You give series neuropsychological test assess memory concentration . You ask complete several questionnaire hospital stay . These questionnaire ask view personality , childhood , quality life , mood variety aspect daily functioning . The questionnaire may complete anytime overnight stay take 2.5 hour finish . On treatment Day 22 , IV line insert one arm hourly blood sample take 2pm , 4pm hourly 6pm 9am . A total 72 ml 's ( approximately 5 tablespoon ) blood drawn . At 2pm Treatment Day 23 , another IV line place arm draw hourly blood sample use measure ACTH cortisol . These blood sample take small amount ( approximately 1 teaspoon ) collect 2pm hour , every hour , start 3pm end 7pm , every 30 minute 12pm . At 3pm , give 0.5mg ( five 0.1mg tablet ) Fludrocortisone . At 4pm , 10 ml blood take Mifepristone concentration . Following last blood draw 12pm , blood sample take clinical laboratory assessment ensure safety follow Fludrocortisone administration . A total 76ml 's ( approximately 5 tablespoon ) blood drawn . The IV line remove vital sign assess . The following morning , study physician contact experimental pharmacy find whether receive placebo ( medication ) mifepristone . If treat mifepristone , mark end study participation research coordinator discuss follow-up assessment . The follow assessment follow : mood assessment perform via phone week 1 2 month 1 , 3 , 6 , 12 completion study . These assessment take maximum 1 hour complete . The physician also confirm continue care treatment primary treat psychiatrist . You discharge GCRC hospital . If placebo , offer 8-day open-label trial mifepristone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Affective Disorders , Psychotic</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<criteria>Inclusion criterion PMD ( individual Psychotic Major Depression ) follow : 1 . DSM IV diagnosis Major Depressive Disorder psychotic feature , Bipolar II Disorder psychotic feature major depressive episode . 2 . 21item HAMD score great equal 21 . 3 . Thase Core Endogenomorphic Scale score great equal 6 item include 21item HDRS . 4 . Between 21 85 year age . 5 . Female patient child bear capacity Psychotic Depression receive treatment mifepristone require use doublebarrier method contraception abstinence entire duration study well thirty day last dose Mifepristone take . 6 . If currently take antipsychotic , antidepressant , anticonvulsant , and/or moodstabilizing medication , must stable medication least oneweek prior enter study . 7 . Preexisting ( current ) primary treat psychiatrist subject psychotic feature . 8 . Any secondary diagnosis anxiety disorder spectrum acceptable . Any secondary diagnosis anxiety disorder spectrum acceptable . Primary preexist chronic ObsessiveCompulsive Disorder ( OCD ) exclusion criterion . Exclusion criterion PMDs follow : 1 . ECT 6 month prior study . 2 . Abuse drug alcohol 6 month prior study . 3 . Unstable untreated hypertension , cardiovascular disease . 4 . If participate blood draw portion protocol , endocrine disorder exclusionary . 5 . Use additional prescription medication , street drug , alcohol week study . 6 . Previous mifepristone failure nonresponse . 7 . Any Axis II diagnosis trait would make participation study difficult . 8 . Current pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>